Allan Shi
About Allan Shi
Allan Shi serves as the Director of Global Market Access for Oncology CAR T Cell Therapy at Kite Pharma, where he leads the market access strategy for new CAR T cell therapy products. With extensive experience in the pharmaceutical industry, he has held key positions at companies such as Bristol-Myers Squibb, AstraZeneca, and Pfizer.
Work at Kite Pharma
Allan Shi serves as the Director of Global Market Access for Oncology CAR T Cell Therapy at Kite Pharma. In this role, he leads the global market access strategy for launching new CAR T cell therapy products. His work focuses on ensuring that innovative therapies reach patients effectively and efficiently, contributing to Kite Pharma's mission to advance cancer treatment.
Professional Background
Allan Shi has extensive experience in the pharmaceutical industry. Before joining Kite Pharma in 2020, he worked at Pfizer Pharmaceuticals for ten years as Director of Global Market Access and Pricing for Rare Disease and Emerging Markets. His previous roles include positions at Bristol-Myers Squibb and AstraZeneca Pharmaceuticals, where he focused on pricing, reimbursement, and market strategy.
Education and Expertise
Allan Shi studied at the University of Pennsylvania's Wharton School, where he gained knowledge in business and management. He also attended the University of Alaska Fairbanks. His expertise lies in engineered T cell therapy, a significant advancement in cancer treatment, positioning him as a knowledgeable leader in the field.
Career Progression
Allan Shi's career spans over two decades in the pharmaceutical sector. He began his career at AstraZeneca Pharmaceuticals, where he worked for seven years in various marketing and pricing roles. He then transitioned to Bristol-Myers Squibb for two years before spending a decade at Pfizer. In 2020, he took on the role of Independent Consultant for ten months before joining Kite Pharma.